Caribou Biosciences, Inc. Other Current Liabilities
Caribou Biosciences, Inc. (CRBU) had Other Current Liabilities of $1.70 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Other Liabilities, Current $1.70M.
- 2026-03-31: Other Liabilities, Current $732.00K.
- 2025-12-31: Other Liabilities, Current $2.68M; Other Liabilities, Current as first filed $816.00K.
- 2025-09-30: Other Liabilities, Current $1.86M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.70M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $732.00K 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $2.68M 10-Q · filed 2026-08-13 | $816.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.86M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $2.07M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $1.54M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.68M 10-K · filed 2026-03-05 | $1.66M 10-K · filed 2025-03-10 |
| 2024-09-30 | $973.00K 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $1.58M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $1.30M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $1.11M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $1.65M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.92M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.66M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $1.37M 10-K · filed 2024-03-11 | $1.21M 10-K · filed 2023-03-09 |
| 2022-09-30 | $1.89M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $1.74M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $800.00K 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $788.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $771.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.70M 10-Q · filed 2021-09-02 | |
| 2020-12-31 | $629.00K 10-K · filed 2022-03-21 | $624.00K 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |